Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Links shared publicly online about this topic.

534
total visits

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.

View full resource at news-medical.net

Tags: Stroke, Thrombotic Event, Disease and Condition, Drug, Pharma, Phase 1 Clinical Trial, News